DK3713919T3 - Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid - Google Patents
Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid Download PDFInfo
- Publication number
- DK3713919T3 DK3713919T3 DK18821779.8T DK18821779T DK3713919T3 DK 3713919 T3 DK3713919 T3 DK 3713919T3 DK 18821779 T DK18821779 T DK 18821779T DK 3713919 T3 DK3713919 T3 DK 3713919T3
- Authority
- DK
- Denmark
- Prior art keywords
- cyclopropylmethyl
- sulfonamide
- quinoline
- piperazine
- carbonyl
- Prior art date
Links
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762589822P | 2017-11-22 | 2017-11-22 | |
US201862691709P | 2018-06-29 | 2018-06-29 | |
PCT/US2018/062197 WO2019104134A1 (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3713919T3 true DK3713919T3 (da) | 2023-09-25 |
Family
ID=64734113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18821779.8T DK3713919T3 (da) | 2017-11-22 | 2018-11-21 | Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid |
Country Status (26)
Country | Link |
---|---|
US (2) | US11254652B2 (da) |
EP (2) | EP3713919B1 (da) |
JP (2) | JP7275130B2 (da) |
KR (1) | KR20200090787A (da) |
CN (2) | CN111372920B (da) |
AU (2) | AU2018373122B2 (da) |
BR (1) | BR112020010185A2 (da) |
CA (1) | CA3081945A1 (da) |
DK (1) | DK3713919T3 (da) |
ES (1) | ES2959764T3 (da) |
FI (1) | FI3713919T3 (da) |
HR (1) | HRP20230931T1 (da) |
HU (1) | HUE063264T2 (da) |
IL (2) | IL274488B2 (da) |
LT (1) | LT3713919T (da) |
MD (1) | MD3713919T2 (da) |
MX (2) | MX2020005348A (da) |
PH (1) | PH12020550644A1 (da) |
PL (1) | PL3713919T3 (da) |
PT (1) | PT3713919T (da) |
RS (1) | RS64592B1 (da) |
SG (1) | SG11202004587XA (da) |
SI (1) | SI3713919T1 (da) |
TW (2) | TWI808108B (da) |
UA (1) | UA127502C2 (da) |
WO (1) | WO2019104134A1 (da) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2012DN00471A (da) * | 2009-06-29 | 2015-06-05 | Agios Pharmaceuticals Inc | |
MX2018014032A (es) | 2017-03-20 | 2019-08-21 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr). |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
MX2021014228A (es) * | 2019-05-22 | 2022-02-21 | Agios Pharmaceuticals Inc | Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. |
US11878049B1 (en) * | 2019-06-14 | 2024-01-23 | Agios Pharmaceuticals, Inc. | Mitapivat therapy and modulators of cytochrome P450 |
EP4097085A1 (en) | 2020-01-28 | 2022-12-07 | Teva Pharmaceuticals International GmbH | Solid state forms of mitapivat and process for preparation thereof |
JP2023542701A (ja) * | 2020-09-25 | 2023-10-11 | アジオス ファーマシューティカルズ, インコーポレイテッド | 薬学的製剤 |
CA3218401A1 (en) | 2021-04-30 | 2022-11-03 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
WO2023154036A1 (en) | 2022-02-08 | 2023-08-17 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
WO2022231627A1 (en) | 2021-04-30 | 2022-11-03 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat for use in treating thalassemia |
EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
AU2022390088A1 (en) | 2021-11-16 | 2024-05-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
WO2024084501A1 (en) | 2022-10-17 | 2024-04-25 | Mylan Laboratories Limited | Crystalline polymorphs of mitapivat and mitapivat hemisulfate |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN191496B (da) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
GB2383042A (en) | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
IN2012DN00471A (da) * | 2009-06-29 | 2015-06-05 | Agios Pharmaceuticals Inc | |
IN2015DN01662A (da) | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
DK3307271T3 (da) * | 2015-06-11 | 2023-10-09 | Agios Pharmaceuticals Inc | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer |
-
2018
- 2018-11-21 AU AU2018373122A patent/AU2018373122B2/en active Active
- 2018-11-21 MD MDE20200988T patent/MD3713919T2/ro unknown
- 2018-11-21 CN CN201880075099.8A patent/CN111372920B/zh active Active
- 2018-11-21 PL PL18821779.8T patent/PL3713919T3/pl unknown
- 2018-11-21 PT PT188217798T patent/PT3713919T/pt unknown
- 2018-11-21 LT LTEPPCT/US2018/062197T patent/LT3713919T/lt unknown
- 2018-11-21 RS RS20230793A patent/RS64592B1/sr unknown
- 2018-11-21 IL IL274488A patent/IL274488B2/en unknown
- 2018-11-21 TW TW107141542A patent/TWI808108B/zh active
- 2018-11-21 US US16/765,456 patent/US11254652B2/en active Active
- 2018-11-21 EP EP18821779.8A patent/EP3713919B1/en active Active
- 2018-11-21 DK DK18821779.8T patent/DK3713919T3/da active
- 2018-11-21 TW TW112118933A patent/TW202334115A/zh unknown
- 2018-11-21 BR BR112020010185-0A patent/BR112020010185A2/pt unknown
- 2018-11-21 CA CA3081945A patent/CA3081945A1/en active Pending
- 2018-11-21 CN CN202311301795.5A patent/CN117551030A/zh active Pending
- 2018-11-21 SI SI201830984T patent/SI3713919T1/sl unknown
- 2018-11-21 IL IL305343A patent/IL305343A/en unknown
- 2018-11-21 HR HRP20230931TT patent/HRP20230931T1/hr unknown
- 2018-11-21 KR KR1020207015018A patent/KR20200090787A/ko active IP Right Grant
- 2018-11-21 UA UAA202003680A patent/UA127502C2/uk unknown
- 2018-11-21 ES ES18821779T patent/ES2959764T3/es active Active
- 2018-11-21 JP JP2020528129A patent/JP7275130B2/ja active Active
- 2018-11-21 MX MX2020005348A patent/MX2020005348A/es unknown
- 2018-11-21 FI FIEP18821779.8T patent/FI3713919T3/fi active
- 2018-11-21 EP EP23186155.0A patent/EP4285904A3/en active Pending
- 2018-11-21 SG SG11202004587XA patent/SG11202004587XA/en unknown
- 2018-11-21 WO PCT/US2018/062197 patent/WO2019104134A1/en active Application Filing
- 2018-11-21 HU HUE18821779A patent/HUE063264T2/hu unknown
-
2020
- 2020-05-15 PH PH12020550644A patent/PH12020550644A1/en unknown
- 2020-07-13 MX MX2022009998A patent/MX2022009998A/es unknown
-
2022
- 2022-01-14 US US17/575,898 patent/US20220220093A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076364A patent/JP2023093762A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200724A patent/AU2024200724A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3713919T3 (da) | Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid | |
DK3866587T3 (da) | Overvågning af husdyr | |
DK3515297T3 (da) | Biosymmetrisk sammenligning af subepidermale fugtværdier | |
DK3883936T3 (da) | Nye heterocykliske forbindelser | |
DK3371171T3 (da) | Inhibitorer af RET | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3596042T3 (da) | Krystalformer af aminolipider | |
DK3565806T3 (da) | Nye phenylderivater | |
DK3798222T3 (da) | Krystallinsk form af den frie base af lorlatinib | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
DK3891145T3 (da) | Modulatorer af trex1 | |
DK3513617T3 (da) | Håndtering af PDCP under genetablering af forbindelse | |
DK3365323T3 (da) | Salte af tetracycliner | |
DK3649781T3 (da) | Forbedring af tvungen grænseopdeling | |
DK3529236T3 (da) | Krystalformer af eravacyclin | |
DK3613436T3 (da) | Oral suspension af temozolomid | |
DK3545614T3 (da) | Pakkebaseret netværk af drivenheder med variabel frekvens | |
DK3743064T3 (da) | Behandling af proteinuri | |
DK3430004T3 (da) | Faststofformer af nilotinibsalte | |
DK3749673T3 (da) | Krystallinsk form af bictegravir-natrium | |
DK3678644T3 (da) | Formuleringer af copanlisib |